Selective application of tumor markers PSA;Gezielter einsatz des tumormarkers PSA

Therapeutische Umschau

Volumn 65, Issue 9, 2008, Pages 493-501

  Kwiatkowski, Maciej ^a   Stieber, Petra ^b   Huber, Andreas R ^a   Recker, Franz ^a  

^a CANTONAL HOSPITAL AARAU   (Switzerland)

^b LUDWIG MAXIMILIANS UNIVERSITY   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

PROSTATE SPECIFIC ANTIGEN; TUMOR MARKER;

CANCER HORMONE THERAPY; CANCER RADIOTHERAPY; EARLY DIAGNOSIS; GLEASON SCORE; HUMAN; LIFE EXPECTANCY; MALE; PROGNOSIS; PROSTATE BIOPSY; PROSTATE CANCER; PROSTATECTOMY; QUALITY OF LIFE; REFERENCE VALUE; REVIEW; SENSITIVITY AND SPECIFICITY;

EID: 52349108878     PISSN: 00405930     EISSN: None     Source Type: Journal    
DOI: 10.1024/0040-930.65.9.493     Document Type: Review

References (43)

1. Srivastava S, Gopal-Srivastava R. Biomarkers in cancer screening: a public health perspective. J Nutr 2002; 132: 2471S-75S.
2. Bensalah K, Montorsi F, Shariat SF. Challenges of cancer biomarker profiling. Eur Urol 2007; 52: 1601-9.
3. Stamey TA, Freiha FS, McNeal JE, Redwine EA, Whittemore AS, Schmid HP. Localized prostate cancer. Relationship of tumor volume to clinical significance for treatment of prostate cancer. Cancer 1993; 71: 933-8.
4. Carroll P, Coley C, McLeod D, et al. Prostate-specific antigen best practice policy - part I: early detection and diagnosis of prostate cancer. Urology 2001; 57: 217-24.
5. Smith RA, Cokkinides V, von Eschenbach AC, et al. American Cancer Society guidelines for the early detection of cancer. CA Cancer J Clin 2002; 52: 8-22.
6. Screening for prostate cancer: recommendation and rationale. Ann Intern Med 2002; 137: 915-6.
7. Bill-Axelson A, Holmberg L, Ruutu M, et al. Radical prostatectomy versus watchful waiting in early prostate cancer. N Engl J Med 2005; 352: 1977-84.
8. D'Amico AV, Moul J, Carroll PR, Sun L, Lubeck D, Chen MH. Cancer-specific mortality after surgery or radiation for patients with clinically localized prostate cancer managed during the prostate-specific antigen era. J Clin Oncol 2003; 21: 2163-72.
9. Jemal A, Murray T, Ward E, et al. Cancer Statistics, 2005. CA Cancer J Clin 2005; 55: 10-30.
10. Schroder FH, Denis LJ, Roobol M, and all participants of the ERSPC. The story of the European Randomized Study of Screening for Prostate Cancer. BJU Int 2003; 92: 1-13.
11. Andriole GL, Levin DL, Crawford ED, et al. Prostate Cancer Screening in the Prostate, Lung, Colorectal and Ovarian (PLCO) Cancer Screening Trial: findings from the initial screening round of a randomized trial. J Natl Cancer Inst 2005; 97: 433-8.
12. Antenor JA, Roehl KA, Eggener SE, Kundu SD, Han M, Catalona WJ. Preoperative PSA and progression-free survival after radical prostatectomy for Stage T1c disease. Urology 2005; 66: 156-60.
13. Kwiatkowski M, Huber A, Stamm B, et al. Features and preliminary results of prostate cancer screening in Canton Aargau, Switzerland. BJU Int 2003; 92 Suppl 2: 44-7.
14. Finne P, Auvinen A, Maattanen L, et al. Diagnostic Value of Free Prostate-Specific Antigen among Men with a Prostate-Specific Antigen Level of < 3.0 mug per Liter. Eur Urol 2007; in press.
15. Carter HB, Epstein JI, Chan DW, Fozard JL, Pearson JD. Recommended prostate-specific antigen testing intervals for the detection of curable prostate cancer. Jama 1997; 277: 1456-60.
16. Smith DS, Catalona WJ, Herschman JD. Longitudinal screening for prostate cancer with prostate-specific antigen. Jama 1996; 276: 1309-15.
17. Rietbergen JB, Kruger AE, Hoedemaeker RF, Bangma CH, Kirkels WJ, Schroder FH. Repeat screening for prostate cancer after 1-year follow-up in 984 biopsied men: clinical and pathological features of detected cancer. J Urol 1998; 160: 2121-5.
18. Hall WH, Jani AB, Ryu JK, Narayan S, Vijayakumar S. The impact of age and comorbidity on survival outcomes and treatment patterns in prostate cancer. Prostate Cancer Prostatic Dis 2005; 8: 22-30.
19. Thompson IM, Pauler DK, Goodman PJ, et al. Prevalence of prostate cancer among men with a prostate-specific antigen level < or = 4.0 ng per milliliter. N Engl J Med 2004; 350: 2239-46.
20. Schroder FH, Bangma CH, Roobol MJ. Is It Necessary to Detect All Prostate Cancers in Men with Serum PSA Levels < 3.0 ng/ml? A Comparison of Biopsy Results of PCPT and Outcome-Related Information from ERSPC. Eur Urol 2008; 53:901-8.
21. Ohori M, Wheeler TM, Dunn JK, Stamey TA, Scardino PT. The pathological features and prognosis of prostate cancer detectable with current diagnostic tests. J Urol 1994; 152: 1714-20.
22. Graif T, Loeb S, Roehl KA, et al. Under diagnosis and over diagnosis of prostate cancer. J Urol 2007; 178: 88-92.
23. Epstein JI, Walsh PC, Brendler CB. Radical prostatectomy for impalpable prostate cancer: the Johns Hopkins experience with tumors found on transurethral resection (stages T1A and T1B) and on needle biopsy (stage T1C). J Urol 1994; 152: 1721-9.
24. Carter CA, Donahue T, Sun L, et al. Temporarily deferred therapy (watchful waiting) for men younger than 70 years and with low-risk localized prostate cancer in the prostate-specific antigen era. J Clin Oncol 2003; 21: 4001-8.
25. Roemeling S, Roobol MJ, Kattan MW, van der Kwast TH, Steyerberg EW, Schroder FH. Nomogram use for the prediction of indolent prostate cancer: impact on screendetected populations. Cancer 2007; 110: 2218-21.
26. Kattan MW, Eastham JA, Wheeler TM, et al. Counseling men with prostate cancer: a nomogram for predicting the presence of small, moderately differentiated, confined tumors. J Urol 2003; 170: 1792-7.
27. Schroder FH, de Vries SH, Bangma CH. Watchful waiting in prostate cancer: review and policy proposals. BJU Int 2003; 92: 851-9.
28. Klotz L. Active surveillance for favorable risk prostate cancer: rationale, risks, and results. Urol Oncol 2007; 25: 505-9.
29. Ward JF, Blute ML, Slezak J, Bergstralh EJ, Zincke H. The long-term clinical impact of biochemical recurrence of prostate cancer 5 or more years after radical prostatectomy. J Urol 2003; 170: 1872-6.
30. Pound CR, Partin AW, Eisenberger MA, Chan DW, Pearson JD, Walsh PC. Natural history of progression after PSA elevation following radical prostatectomy. Jama 1999; 281: 1591-7.
31. Amling CL, Bergstralh EJ, Blute ML, Slezak JM, Zincke H. Defining prostate specific antigen progression after radical prostatectomy: what is the most appropriate cut point? J Urol 2001; 165: 1146-51.
32. Kattan MW, Wheeler TM, Scardino PT. Postoperative nomogram for disease recurrence after radical prostatectomy for prostate cancer. J Clin Oncol 1999; 17: 1499-507.
33. rd, Hanks G, Thames H, Jr, et al. Defining biochemical failure following radiotherapy with or without hormonal therapy in men with clinically localized prostate cancer: recommendations of the RTOG-ASTRO Phoenix Consensus Conference. Int J Radiat Oncol Biol Phys 2006; 65: 965-74.
34. Albertsen PC, Hanley JA, Penson DF, Fine J. Validation of increasing prostate specific antigen as a predictor of prostate cancer death after treatment of localized prostate cancer with surgery or radiation. J Urol 2004; 171: 2221-5.
35. D'Amico AV, Moul JW, Carroll PR, Sun L, Lubeck D, Chen MH. Surrogate end point for prostate cancer-specific mortality after radical prostatectomy or radiation therapy. J Natl Cancer Inst 2003; 95: 1376-83.
36. Okotie OT, Aronson WJ, Wieder JA, et al. Predictors of metastatic disease in men with biochemical failure following radical prostatectomy. J Urol 2004; 171: 2260-4.
37. Schild SE, Buskirk SJ, Wong WW, et al. The use of radiotherapy for patients with isolated elevation of serum prostate specific antigen following radical prostatectomy. J Urol 1996; 156: 1725-9.
38. Song DY, Thompson TL, Ramakrishnan V, et al. Salvage radiotherapy for rising or persistent PSA after radical prostatectomy. Urology 2002; 60: 281-7.
39. Ward JF, Zincke H, Bergstralh EJ, Slezak JM, Blute ML. Prostate specific antigen doubling time subsequent to radical prostatectomy as a prognosticator of outcome following salvage radiotherapy. J Urol 2004; 172: 2244-8.
40. Rogers E, Ohori M, Kassabian VS, Wheeler TM, Scardino PT. Salvage radical prostatectomy: outcome measured by serum prostate specific antigen levels. J Urol 1995; 153: 104-10.
41. Ward JF, Sebo TJ, Blute ML, Zincke H. Salvage surgery for radiorecurrent prostate cancer: contemporary outcomes. J Urol 2005; 173: 1156-60.
42. Moul JW, Wu H, Sun L, et al. Early versus delayed hormonal therapy for prostate specific antigen only recurrence of prostate cancer after radical prostatectomy. J Urol 2004; 171: 1141-7.
43. The Medical Research Council Prostate Cancer Working Party Investigators Group. Immediate versus deferred treatment for advanced prostatic cancer: initial results of the Medical Research Council Trial. Br J Urol 1997; 79: 235-46.